Skip to main content
SpringerLink
Log in

Urinary Excretion of N-Acetyl-β-D-Glucosaminidase and Epidermal Growth Factor in Paediatric Patients Receiving Cefixime Prophylaxis for Recurrent Urinary Tract Infections

  • Clinical Pharmacodynamics
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective

To determine the urinary excretion of N-acetyl-β-D-glucosaminidase (NAG; early index of renal proximal tubular damage) and epidermal growth factor (EGF; early index of renal damage repair) in paediatric patients with and without vesico-ureteric reflux (VUR) receiving prophylactic cefixime for recurrent urinary tract infections (UTIs).

Design and Setting

Urinary levels of NAG and EGF in children, with and without VUR, with recurrent UTIs receiving prophylactic cefixime were compared with normal paediatric laboratory values in a university paediatric department. All children were followed during an ordinary admission or in a day hospital.

Participants and Treatment

The study population consisted of 27 patients (15 males, 12 females; mean age 1.73 ± 1.43 years) followed in the Paediatric Department of the University of Verona for recurrent UTIs. All patients had experienced at least two episodes of UTIs in the previous 2 months. Patients received antibiotic prophylaxis with cefixime (4 mg/kg bodyweight), administered as a single bedtime dose. The overall duration of the treatment ranged from 1 to 2 months. Urine samples and cultures were taken immediately prior to voiding urethrocystography via the bladder catheter and were immediately frozen at —20°C. NAG activity and EGF levels in the urine were determined using a colorimetric assay and a radioimmunoassay, respectively. The urinary creatinine level was determined using the Jaffe kinetic colorimetric method at a constant reaction temperature of 37°C. The values obtained were compared with the Laboratory’s own reference standards for paediatric patients.

Main Outcome Measures and Results

All children in the study population presented with normal routine laboratory values, in particular serum creatinine and BUN levels. In addition, urine tests and cultures yielded normal values in all cases. In patients without VUR receiving prophylactic cefixime, the mean [±standard deviation (SD)] NAG level was 0.50 ± 0.30 U/mmol creatinine (range0.05 to 1.17). Only one of 20 patients had a slight increase above the normal range. In patients with VUR, the urinary NAG level was 2.55 ± 1.66 U/mmol creatinine (range 1.37 to 6), with all seven patients having abnormally elevated NAG values. The difference in NAG levels between the two groups was statistically significant (p < 0.001). In patients receiving prophylactic cefixime without VUR (group 1), the mean urinary EGF level was 25.06 ± 16.05 μg/L (range 1.58 to 49.63). In patients receiving prophylaxis with cefixime with VUR treatment (group 2), the mean (± SD) urinary EGF level was 38.23 ± 33.99 μg/L (range 14.4 to 107). Urinary EGF levels were not statistically different between group 1 and normal levels, whereas in group 2, EGF levels were significantly higher than normal levels or those of group 1 (p < 0.05, both comparisons).

Conclusions

Prophylactic treatment with cefixime was well tolerated, including renally, in children with recurrent UTIs without VUR. Renal tolerability was assessed using a sensitive measure of the early signs of nephrotoxicity, such as urinary NAG values, and markers of damage repair, such as urinary EGF levels. The presence of VUR in patients was associated with significant renal proximal tubular damage, as reflected in elevated urinary NAG values. The high urinary EGF values probably reflect the compensatory repair action of the kidney in patients with VUR. In conclusion, in clinical practice, cefixime may be safely suggested for antibiotic prophylaxis in paediatric patients with recurrent UTIs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zelicovich I, Adelman RD, Nancarrow PA. Urinary tract infections in children. An update. West J Med 1992; 157: 554–61

    Google Scholar 

  2. Fanos V, Agostiniani R, Cataldi L. Pyelectasis and hydro-nephrosis in the newborn and infant. Acta Pediatr 2000; 89: 200–4

    Article  Google Scholar 

  3. Quinet B. Définition actuel de l’infection urinaire de l’enfant. Arch Pediat 1998; Suppl. 3: 250–3

    Article  Google Scholar 

  4. Bitar CN, Steele RW. Use of prophylactic antibiotics in children. Adv Pediatr Infect Dis 1995; 10: 227–62

    PubMed  CAS  Google Scholar 

  5. Mangiarotti P, Pizzini C, Fanos V. Antibiotic prophylaxis in children with relapsing urinary tract infections. J Chemother 2000; 12(2): 115–23

    PubMed  CAS  Google Scholar 

  6. Fanos V, Dall’Agnola A. Antibiotics in neonatal infections: a review. Drugs 1999, 58(3): 406–27

    Article  Google Scholar 

  7. Fanos V, Cataldi L. Antibacterial induced nephrotoxicity in the newborn. Drug Safety 1999; 20(3): 245–67

    Article  PubMed  CAS  Google Scholar 

  8. Brittain DC, Scull BE, Hirose T, et al. The pharmacokinetic and bactericidal characteristics of oral cefixime. Clin Pharmacol Ther 1985; 38(5): 590–4

    Article  PubMed  CAS  Google Scholar 

  9. Barry AL, Jones RN. Cefixime: spectrum of antibacterial activity against 16016 clinical isolates. Pediatr Infect Dis J 1987; 6: 954–7

    Article  PubMed  CAS  Google Scholar 

  10. Brodgen RN, Campoli-Richards DM. Cefixime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1989; 38: 524–50

    Article  Google Scholar 

  11. Neu HC. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime. Pediatr Infect Dis J 1987; 6: 954–7

    Article  Google Scholar 

  12. Tally FP, Cartwright K, Desjardins RE, et al. Safety profile of cefixime. Pediatr Infect Dis J 1987; 6: 976–80

    Article  PubMed  CAS  Google Scholar 

  13. Mussap M, Fanos V, Cataldi L, et al. Urinary low molecular mass proteins and enzymes as early, non invasive markers of nephrotoxicity in the neonate. Eur J Lab Med 1998; 6(1): 1–14)

    Google Scholar 

  14. Savage CR Jr, Inagami T, Cohen S. The primary structure of epidermal growth factor. J Biol Chem 1972; 247: 7612–21

    PubMed  CAS  Google Scholar 

  15. Savage CR Jr, Hash JH, Cohen S. Epidermal growth factor, location of disulfide bonds. J Biol Chem 1973; 248: 7669–72

    PubMed  CAS  Google Scholar 

  16. Hofmann GE, Abramowicz JS. Epidermal growth factor (EGF) concentrations in amniotic fluid and maternal urine during pregnancy. Acta Obstet Gynecol Scand 1990; 69(3): 217–21

    Article  PubMed  CAS  Google Scholar 

  17. Mattila AL, Perheemtupa J, Pesonen K, et al. Epidermal growth factor in human urine from birth to puberty. J Clin Endocrinol Metab 1985; 61: 997–1000

    Article  PubMed  CAS  Google Scholar 

  18. Stoll DM, King LE Jr, McNeil L, et al. Human urinary epidermal growth factor excretion: age, sex, and race dependence. J Clin Endocrinol Metab 1988; 67: 361–7

    Article  PubMed  CAS  Google Scholar 

  19. Hirata Y, Moore GW, Bertagna C, et al. Plasma concentration of immunoreactive human epidermal growth factor (uro-gastrone) in man. J Clin Endocrinol Metab 1980; 50: 440–4

    Article  PubMed  CAS  Google Scholar 

  20. Dagogo-Jack S. Epidermal growth factor EGF in human saliva: effect of age, sex, race, pregnancy and sialogogue. Scand J Gastroenterol 1986; 124 Suppl.: 47–54

    Article  CAS  Google Scholar 

  21. Plebani M, Fanos V, Mussap M, et al. Urinary excretion of human epidermal growth factor in premature infants requiring assisted ventilation over the first week of life. Nephron 1997; 76: 225–6

    Article  PubMed  CAS  Google Scholar 

  22. Callegari C, Laborde NP, Buenaflor G, et al. The source of urinary epidermal growth factor in humans. Eur J Appl Physiol 1988; 58: 26–31

    Article  CAS  Google Scholar 

  23. Salido EC, Lakshmanan J, Fisher DA, et al. Immunocyto-chemical localization of epidermal growth factor prohormone in adult human kidney. Clin Res 1991; 39: 112A

    Google Scholar 

  24. Humes HD, Cieslinski DA, Coimbra TM, et al. Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure. J Clin Invest 1989; 84: 1757–61

    Article  PubMed  CAS  Google Scholar 

  25. Kanda S, Saha PK, Nomata K, et al. Transient increase in renal epidermal growth factor content after unilateral nephrectomy in the mouse. Acta Endocrinol Copenh 1991 Feb; 124(2): 188–93

    PubMed  CAS  Google Scholar 

  26. Vinter Jensen L, Smerup M, Jørgensen PE, et al. Chronic treatment with epidermal growth factor stimulates growth of the urinary tract in the rat. Urol Res 1996; 24: 15–21

    Article  Google Scholar 

  27. Csàthy L, Pòcsi I. Urinary N-acetyl-β-D-glucosaminidase determination in newborns and children: methods and diagnostic applications. Eur J Clin Chem Clin Biochem 1995; 33: 575–87

    PubMed  Google Scholar 

  28. Olah VA, Csàthy L, Varga J, et al. Reference ranges for urinary N-acetyl-β-D-glucosaminidase in healthy children determined with three colorimetric methods. Ann Clin Biochem 1994; 31: 87–8

    PubMed  CAS  Google Scholar 

  29. Neu HC, Chin NX, Labthavikul P. Comparative in vitro activity and β-lactamase stability of FR-17027, a new orally active cephalosporin. Antimicrob Agents Chemother 1984; 26: 174–80

    Article  PubMed  CAS  Google Scholar 

  30. Pennie RA. Cefixime in pediatric infections. In: Adam D, Quintiliani R, editors. Cefixime. Torre Lazur: McCann 2000: 79–83

    Google Scholar 

  31. Dagan R, Einhorn M, Lang R, et al. Once daily cefixime compared with twice daily trimethoprim/sulfamethoxazole for treatment of urinary tract infection in infants and children. Pediatr Infect Dis J 1992; 11: 98–203

    Google Scholar 

  32. Pizzini C, Mussap P, Mangiarotti P, et al. Urinary biomarkers in children with and without reflux on antibiotic prophylaxis with cefaclor. Clin Drug Invest 1999; 18(6): 461–6

    Article  CAS  Google Scholar 

  33. Fanos V, Agostiniani R, Cataldi L. Vesicoureteric reflux: an update. Pediatr Med Chir 1999; 21(2): 47–56

    PubMed  CAS  Google Scholar 

  34. Cunha BA. Third generation cephalosporines: a review. Clin Ther 1992; 14: 616–52

    PubMed  CAS  Google Scholar 

  35. Norrby SR. Adverse reactions and interactions with newer cephalosporins and cephamycin antibiotics. Med Toxicol 1986; 1: 32–46

    PubMed  CAS  Google Scholar 

  36. Tune BM. Renal tubular transport and nephrotoxicity of beta-lactam antibiotics: structure-activity relationship. Miner Electrolyte Metab 1994; 20: 221–31

    PubMed  CAS  Google Scholar 

  37. Tune BM. Nephrotoxicity of beta-lactam antibiotics: mechanism and strategies for prevention. Pediatr Nephrol 1997; 11(6): 768–72

    Article  PubMed  CAS  Google Scholar 

  38. Kaloyanides GJ. Antibiotic related nephrotoxicity. Nephrol Dial Transplant 1994; 9(4 Suppl.): 130S–40S

    Google Scholar 

  39. Morin JP, Fillastre JP, Vaillant R. In vitro effects of amino-glycosides and cephalosporins on rat kidney lysosomes. C R Seances Soc Biol Fil 1977; 171(5): 1088–93

    PubMed  CAS  Google Scholar 

  40. Naruse T, Hirokawa N, Oike S. Clinical evaluation of urinary N-acetyl-beta-D-glucosaminidase activity in patients receiving aminoglycoside and cephalosporin drugs. Res Commun Chem Pathol Pharmacol 1981; 31(2): 313–29

    PubMed  CAS  Google Scholar 

  41. Furukawa S, Okada T. Clinical experience with cefixime in pediatric infections (in Japanese). Jpn J Antibiot 1986; 39(4): 1128–37

    PubMed  CAS  Google Scholar 

  42. Mikawa H, Mayumi M, Akiyama Y, et al. Clinical studies on cefixime in pediatrics [in Japanese]. Jpn J Antibiot 1989 Dec; 42(12): 2527–39

    PubMed  CAS  Google Scholar 

  43. Risser WL, Barone JS, Clark PA, et al. Noncomparative, open label, multicenter trial of cefixime for treatment of bacterial pharyngitis, cystitis and pneumonia in pediatric patients. Pediatr Infect Dis J 1987 Oct; 6(10): 1002–6

    Article  PubMed  CAS  Google Scholar 

  44. Tally FP, Cartwright K, Desjardins RE, et al. Safety profile of cefixime. Pediatr Infect Dis J 1987; 6: 976–80

    Article  PubMed  CAS  Google Scholar 

  45. Garcia Rodriguez JA, Munoz Bellido JL. Therapeutic use of cefixime in urinary tract infections infections. In: Adam D, Quintiliani R, editors. Cefixime. Torre Lazur: McCann, 2000: 95–101

    Google Scholar 

  46. Fanos V, Cataldi L. Cefixime in urinary tract infections with particular reference to pediatrics. J Chemother 2001; 13(2): 112–7

    PubMed  CAS  Google Scholar 

  47. Fanos V, Pizzini C, Mussap M, et al. Urinary epidermal growth factor in different renal conditions. Ren Fail. In press

  48. Cuzzolin L, Mangiarotti P, Fanos V. Urinary PGE2 concentrations measured by a new EIA method in infants with urinary tract infections or renal malformations. Prostaglandins Leukot Essent Fatty Acids. In press

Download references

Author information

Authors and Affiliations

  1. Clinica Pediatrica, Università di Verona, Via delle Menegone 10, 37134, Verona, Italy

    Vassilios Fanos, D. Osio & C. Pizzini

  2. Department of Laboratory Medicine, University-Hospital, Padova, Italy

    M. Mussap & M. Plebani

  3. Biomedical Research Center, Castelfranco Veneto, Regione Veneto, Italy

    M. Plebani

Authors
  1. Vassilios Fanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Mussap
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Osio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Pizzini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Plebani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vassilios Fanos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fanos, V., Mussap, M., Osio, D. et al. Urinary Excretion of N-Acetyl-β-D-Glucosaminidase and Epidermal Growth Factor in Paediatric Patients Receiving Cefixime Prophylaxis for Recurrent Urinary Tract Infections. Clin. Drug Investig. 21, 511–518 (2001). https://doi.org/10.2165/00044011-200121070-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200121070-00007

Keywords

Search

Navigation